Fundamental Analysis of RENALYTIX AI PLC-ADR(NASDAQ:RNLX) stock

Fundamental Rating

Overall RNLX gets a fundamental rating of 2 out of 10. We evaluated RNLX against 40 industry peers in the Health Care Technology industry. RNLX has a bad profitability rating. Also its financial health evaluation is rather negative. RNLX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

RNLX had negative earnings in the past year.

In the past year RNLX has reported a negative cash flow from operations.

In the past 5 years RNLX always reported negative net income.

RNLX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RNLX has a Return On Assets of -109.75%. This is amonst the worse of the industry: RNLX underperforms 82.05% of its industry peers.

The Return On Equity of RNLX (-250.48%) is worse than 82.05% of its industry peers.

		Industry Rank	Sector Rank
ROA	-109.75%
ROE	-250.48%
ROIC	N/A

ROA(3y)-76.55%

ROA(5y)-54.96%

ROE(3y)-138.17%

ROE(5y)-92.72%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RNLX's Gross Margin of 20.60% is on the low side compared to the rest of the industry. RNLX is outperformed by 89.74% of its industry peers.

The Profit Margin and Operating Margin are not available for RNLX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	20.6%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for RNLX has been increased compared to 1 year ago.

Compared to 5 years ago, RNLX has more shares outstanding

Compared to 1 year ago, RNLX has a worse debt to assets ratio.

2.2 Solvency

RNLX has an Altman-Z score of -4.99. This is a bad value and indicates that RNLX is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of RNLX (-4.99) is worse than 76.92% of its industry peers.

RNLX has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.

RNLX has a Debt to Equity ratio (0.41) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Altman-Z	-4.99

ROIC/WACCN/A

WACC7.69%

2.3 Liquidity

A Current Ratio of 1.76 indicates that RNLX should not have too much problems paying its short term obligations.

RNLX's Current ratio of 1.76 is in line compared to the rest of the industry. RNLX outperforms 46.15% of its industry peers.

A Quick Ratio of 1.71 indicates that RNLX should not have too much problems paying its short term obligations.

With a Quick ratio value of 1.71, RNLX perfoms like the industry average, outperforming 46.15% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.76
Quick Ratio	1.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.23% over the past year.

The Revenue has grown by 14.58% in the past year. This is quite good.

EPS 1Y (TTM)27.23%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q65.39%

Revenue 1Y (TTM)14.58%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-24.41%

3.2 Future

The Earnings Per Share is expected to grow by 21.35% on average over the next years. This is a very strong growth

RNLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 73.89% yearly.

EPS Next Y59.3%

EPS Next 2Y32.95%

EPS Next 3Y21.35%

EPS Next 5YN/A

Revenue Next Year39.85%

Revenue Next 2Y68.91%

Revenue Next 3Y73.89%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RNLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year RNLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

RNLX's earnings are expected to grow with 21.35% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.95%

EPS Next 3Y21.35%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RNLX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

RENALYTIX AI PLC-ADR

NASDAQ:RNLX (4/18/2024, 7:17:56 PM)

0.785

-0.04 (-5.42%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap47.07M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-109.75%
ROE	-250.48%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	20.6%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.08

Health

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.76
Quick Ratio	1.71
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)27.23%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y59.3%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)14.58%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

RENALYTIX AI PLC-ADR (RNLX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens